Stahl's Essential Psychopharmacology Online
In Collaboration With
Index
The 
-icon indicates content; the 
-icon indicates figures; the 
-icon indicates tables.
- major depressive disorder, , ,
- affective symptoms,
- as prodrome of Alzheimer’s disease,
- disease progression concept,
- in perimenopausal women,
- symptom overlap with anxiety disorders,
- use of combination antidepressant therapies,
- mania, ,
- and psychosis,
- antidepressant induced,
- antimanic actions of atypical antipsychotics,
- in children and adolescents,
- mild mania,
- symptoms and circuits, . See also mood disorders
- MAO.. monoamine oxidase
- MAOIs.. monoamine oxidase inhibitors
- MAPK (MAP kinase, mitogen activated protein kinase),
- maprotiline, ,
- marijuana,
- and schizophrenia,
- brain's own (anandamide),
- effect on appetite,
- effects of,
- MC4R agonists,
- MDMA (3,4-methylene-dioxymethamphetamine), ,
- meclobemide,
- mehylone,
- MEK (MAP kinase/ERK kinase or mitogen-activated protein kinase kinase/extracellular
signal- regulated kinase kinase),
- melancholic depression,
- melanin-concentrating hormone,
- melanocyte 4 receptors (MC4Rs),
- melatonergic hypnotics,
- melatonin,
- melatonin secretion
- and depression,
- Mellaril,
- memantine,
- memory disturbance.. See dementia.
- meperidine,
- mephedrone,
- mescaline,
- mesolimbic dopamine circuit
- pathway of reward in impulsive–compulsive disorders,
- mesoridazine,
- metabolic disease risk
- atypical antipsychotics,
- metabotropic glutamate receptors (mGluRs)
- presynaptic antagonists/postsynaptic agonists,
- metformin,
- methadone, ,
- methionine synthase,
- methionine synthase reductase,
- methylation of histones,
- methylenedioxypyrovalerone (MDPV),
- methylenetetrahydrofolate reductase
- genetic variants,
- l-methylfolate, ,
- mood-stabilizing properties,
- methylphenidate, , ,
- ADHD treatment,
- wake-promoting agent,
- methyltransferases,
- methyprylon,
- mianserin, ,
- mild cognitive impairment (MCI)
- distinction from normal aging,
- milnacipran
- properties,
- mirtazapine, , , , , , ,
- California rocket fuel (SNRI plus mirtazapine), ,
- mitochondria,
- mivacurium,
- mixed state mood disorders, ,
- antidepressant induced,
- MK-4305 (suvorexant),
- MK-6096,
- modafinil
- mode of action,
- mood-stabilizing properties,
- monoamine hypothesis of depression, ,
- monoamine neurons
- volume neurotransmission at autoreceptors,
- monoamine neurotransmitters
- and mood disorders,
- monoamine oxidase (MAO),
- monoamine oxidase A (MAO-A), , , ,
- and depression,
- reversible inhibitors of MAO-A (RIMAs),
- monoamine oxidase B (MAO-B), , , ,
- monoamine oxidase inhibitors (MAOIs),
- avoidance of serotonergic agents,
- clinical management solutions,
- dietary tyramine interaction,
- drug–drug interactions,
- interactions with analgesics,
- interactions with anesthetics,
- interactions with decongestants,
- interactions with opiates,
- interactions with tricyclic antidepressants,
- MAO-A activity and depression,
- MAO subtypes,
- myths and misinformation,
- reversible inhibitors of MAO-A (RIMAs),
- risk of hypertensive crisis,
- risk of serotonin toxicity/serotonin syndrome,
- switching to and from,
- sympathomimetics to avoid or administer with caution,
- monoamine receptor hypothesis of depression
- and gene expression,
- monoamine transporter blockers,
- monoamine transporters (SLC6 family)
- psychotropic drug targets,
- monoamines
- interactions between,
- mood disorders,
- affective symptoms of schizophrenia,
- and hyperthymic temperament,
- and monoamine neurotransmitters,
- bipolar depression,
- bipolar disorder NOS (not otherwise specified),
- bipolar spectrum,
- bipolar ¼ (0.25) disorder,
- bipolar ½ (0.5) disorder,
- bipolar I disorder,
- bipolar I ½ (1.5) disorder,
- bipolar II disorder,
- bipolar II ½ (2.5) disorder,
- bipolar III (3.0) disorder,
- bipolar III ½ (3.5) disorder,
- bipolar IV (4.0) disorder,
- bipolar V (5.0) disorder,
- bipolar VI (6.0) disorder,
- bipolarity comorbid with dementia,
- caused by antidepressants,
- continuum disease model,
- cyclothymic disorder, ,
- depression,
- depression symptoms and circuits,
- depression with hypomania,
- depressive temperament,
- description,
- dichotomous disease model,
- distinguishing unipolar from bipolar depression,
- double depression,
- dysthymia,
- future treatments,
- hyperthymic temperament,
- hypomania,
- major depressive disorder, ,
- mania,
- mania symptoms and circuits,
- mild mania,
- mixed mood state,
- monoamine hypothesis of depression,
- monoamine receptor hypothesis and gene expression,
- mood-centered perspective,
- mood chart,
- mood-related temperaments,
- natural history,
- neuroimaging,
- neurotransmitter systems involved,
- pain associated with,
- pain symptoms,
- question of progression,
- range of moods,
- rapid cycling,
- related to substance abuse,
- relationship to psychotic disorders,
- schizoaffective disorder,
- schizo-bipolar disorder,
- stress and depression,
- unipolar depression,
- mood stabilizer selection,
- adolescents,
- benzodiazepines,
- Boston bipolar brew,
- breastfeeding patient,
- California careful cocktail,
- carbamazepine combinations,
- children,
- combinations of mood stabilizers,
- first-line treatments in bipolar disorder,
- innovative “eminence-based” combinations,
- Lami-quel combination,
- lamotrigine combinations, ,
- lithium combinations,
- monotherapy trials,
- pregnant patient,
- quetiapine combinations,
- Tennessee mood shine,
- valproate combinations,
- women and bipolar disorder,
- mood stabilizers
- anticonvulsants,
- antipsychotics,
- armodafinil,
- atypical antipsychotics,
- benzodiazepines,
- definitions,
- future developments,
- inositol,
- lithium,
- l-methylfolate,
- modafinil,
- omega-3 fatty acids (EPA and DHA),
- risks related to antidepressants,
- thyroid hormones,
- morphine, ,
- brain's own (endorphins),
- motivational therapies,
- motor disturbances in psychosis,
- motor hyperactivity,
- mRNA,
- mTOR (mammalian target of rapamycin) pathway,
- multi-infarct dementia
- cognitive symptoms,
- muscarine,
- muscarinic cholinergic receptors,
- blockade by conventional antipsychotics,